MRNS - MARINUS PHARMACEUTICALS, INC.
IEX Last Trade
0.334
0.018 5.269%
Share volume: 8,294
Last Updated: Thu 26 Dec 2024 08:27:36 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$0.32
0.02
5.56%
Fundamental analysis
32%
Profitability
25%
Dept financing
30%
Liquidity
75%
Performance
30%
Performance
5 Days
8.07%
1 Month
-20.07%
3 Months
-85.13%
6 Months
-79.59%
1 Year
-97.62%
2 Year
-92.78%
Key data
Stock price
$0.33
DAY RANGE
$0.25 - $0.32
52 WEEK RANGE
$0.24 - $11.26
52 WEEK CHANGE
-$97.66
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Scott N. Braunstein
Region: US
Website: marinuspharma.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: marinuspharma.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Marinus Pharmaceuticals, Inc. offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome.
Recent news